ArticleNeurology and therapy2016
Neuropsychiatric Adverse Reactions to Mefloquine: a Systematic Comparison of Prescribing and Patient Safety Guidance in the US, UK, Ireland, Australia, New Zealand, and Canada.
Article in Neurology and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Review
- Structural basis of connexin-36 gap junction channel inhibition.Cell discovery · 2024Article
- An In Silico and In Vitro Assessment of the Neurotoxicity of Mefloquine.Biomedicines · 2024Article
- Mechanism of connexin channel inhibition by mefloquine and 2-aminoethoxydiphenyl borate.PloS one · 2024Article
- Continuous release of mefloquine featured in electrospun fiber membranes alleviates epidural fibrosis and aids in sensory neurological function after lumbar laminectomy.Materials today. Bio · 2022Article
- A Comparison of Safety Information in Drug Labeling at the Initial Approval of New Drugs Approved Both in Japan and the United States.Therapeutic innovation & regulatory science · 2022Article
- Mefloquine as a prophylaxis for malaria needs to be revisited.International journal for parasitology. Drugs and drug resistance · 2021Review
- Differential Stabilities of Mefloquine-Bound Human andACS omega · 2021Article
- Targeting liver stage malaria with metformin.JCI insight · 2019Article
- Bias and Confounding in Studies of Chronic Mental Health Effects from Mefloquine Exposure.The American journal of tropical medicine and hygiene · 2019Article
- Activity of mefloquine and mefloquine derivatives against Echinococcus multilocularis.International journal for parasitology. Drugs and drug resistance · 2018Article
- Measurement of Mefloquine Exposure in Studies of Veterans' Sleep Disorders.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2018Article
- A serious nightmare: psychiatric and neurologic adverse reactions to mefloquine are serious adverse reactions.Pharmacology research & perspectives · 2017Article
- Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesis.Nature microbiology · 2017Article
- Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data.Drugs in R&D · 2017Article
- Screening for Symptomatic Mefloquine Exposure Among Veterans With Chronic Psychiatric Symptoms.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2017Article
- Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients.PloS one · 2017Article
- FDA Black Box, VA Red Ink? A Successful Service-Connected Disability Claim for Chronic Neuropsychiatric Adverse Effects From Mefloquine.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2016Article
- Psychiatric effects of malaria and anti-malarial drugs: historical and modern perspectives.Malaria journal · 2016Review
- Implications of Changes to the Mefloquine Product Monograph.The Canadian journal of hospital pharmacyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe antimalarial drug mefloquine (MQ) is associated with neuropsychiatric adverse reactions, some of which may predict the development of more serious effects. Although prescribing guidance in the United States drug label (DL) recommends to discontinue MQ at the onset of neuropsychiatric symptoms, only certain reactions are listed in both the DL and the corresponding patient medication guide with a recommendation to discontinue or to consult a physician should they occur. To identify possible prodromal reactions for which there is complete or partial agreement in prescribing and patient recommendations, a systematic comparison of international drug safety labeling was performed.
methodsThe full text of each DL and medication guide (or equivalent) from six primarily English-speaking countries was reviewed to identify specific reactions with corresponding recommendations in drug safety labeling. Percentage agreement across the countries in corresponding recommendations was determined by MedDRA(®) high level group term (HLGT).
resultsRecommendations were found for reactions in 22 neuropsychiatric HLGTs. Complete or partial international agreement was found for reactions in 11 (50%) HLGTs.
conclusionThis analysis suggests opportunities for physicians to improve patient counseling and for international drug regulators to clarify language in MQ safety labeling to reflect national risk-benefit considerations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.